Tatlı Doğan Hayriye, Doğan Mehmet, Kahraman Seda, Çanakçı Doğukan, Şendur Mehmet Ali Nahit, Tahtacı Mustafa, Erdoğan Fazlı
Department of Pathology, Faculty of Medicine, Ankara Bilkent City Hospital, Ankara Yıldırım Beyazıt University, Ankara 06800, Turkey.
Department of Medical Oncology, Ankara Yıldırım Beyazıt University, Ankara 06800, Turkey.
Diagnostics (Basel). 2025 Jan 14;15(2):184. doi: 10.3390/diagnostics15020184.
: As colorectal cancers are histopathologically and molecularly highly heterogeneous tumors, it is necessary to consider the tumor's microenvironment as well as its cellular characteristics in order to determine the biological behavior of the tumor. This study included 100 patients who underwent resection for colorectal cancer. We aimed to investigate the relationships between the expression status of the HIF-1α, LOX and ITGA5 proteins and clinicopathologic parameters. : HIF-1α, LOX and ITGA5 antibodies were applied immunohistochemically to tissue microarrays prepared from tumor samples. Expression status in the tumor microenvironment were evaluated using a combined scoring system based on staining intensity and the percentage of positively stained cells. Nuclear HIF-1α expression in tumor cells was quantified, with >1% considered positive. The staining of HIF-1α, ITGA5 and LOX was analyzed in relation to prognostic and molecular features. : The staining of HIF-1α, ITGA5 and LOX in the tumor microenvironment demonstrated a positive correlation with one another and with HIF-1α and LOX expression in tumor cells. In patients with KRAS, NRAS or BRAF mutation and the moderate to strong expression of all three of these proteins in the tumor microenvironment, the number of metastatic lymph nodes was higher than in other patients. Stage IV patients with the moderate to strong expression of HIF-1α, ITGA5 or LOX in the microenvironment had lower progression-free survival than those with weak expression ( < 0.05). In addition, female gender; moderate to strong HIF-1α, LOX and ITGA5 stromal expression; and metastatic first line chemotherapy only were found to be independently associated with an increased risk of progression. : These markers may be useful in predicting treatment responses and may also guide the development of alternative or combined treatments that specifically target molecules such as HIF and LOX. Our study should be supported by more comprehensive studies addressing the tumor stroma and its prognostic importance.
由于结直肠癌是组织病理学和分子水平上高度异质性的肿瘤,为了确定肿瘤的生物学行为,有必要考虑肿瘤的微环境及其细胞特征。本研究纳入了100例行结直肠癌切除术的患者。我们旨在研究缺氧诱导因子-1α(HIF-1α)、赖氨氧化酶(LOX)和整合素α5(ITGA5)蛋白的表达状态与临床病理参数之间的关系。:将HIF-1α、LOX和ITGA5抗体免疫组织化学应用于从肿瘤样本制备的组织微阵列。使用基于染色强度和阳性染色细胞百分比的综合评分系统评估肿瘤微环境中的表达状态。对肿瘤细胞中的核HIF-1α表达进行定量,>1%视为阳性。分析了HIF-1α、ITGA5和LOX的染色与预后和分子特征的关系。:肿瘤微环境中HIF-1α、ITGA5和LOX的染色相互之间以及与肿瘤细胞中HIF-1α和LOX的表达呈正相关。在KRAS、NRAS或BRAF突变且肿瘤微环境中这三种蛋白均呈中度至强表达的患者中,转移淋巴结的数量高于其他患者。微环境中HIF-1α、ITGA5或LOX呈中度至强表达的IV期患者的无进展生存期低于弱表达患者(<0.05)。此外,女性;HIF-1α、LOX和ITGA5基质呈中度至强表达;以及仅一线转移性化疗被发现与进展风险增加独立相关。:这些标志物可能有助于预测治疗反应,也可能指导针对HIF和LOX等特定分子的替代或联合治疗的开发。我们的研究应得到更多针对肿瘤基质及其预后重要性的综合研究的支持。